Glutamate Reducing Interventions in Schizophrenia

Status Completed

Clinical Trial Summary

Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to determine whether these doses of POMA are affecting glutamate levels.

Clinical Trial Description

A double-blind, randomized, phase 1b, multiple dose trial of 14 days of treatment with POMA (80 mg, 160 mg, 240 mg, 320 mg) in clinical high risk patients to determine which dose, if any, reduces glutamate and metabolism using MRI techniques. The GO NO-GO decision will be whether or not any dose tested in the R61 phase of the trial decreases left hippocampal CA1 region cerebral blood volume (CBV). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03321617
Study type	Interventional
Source	New York State Psychiatric Institute
Contact
Status	Completed
Phase	Phase 1
Start date	April 17, 2018
Completion date	March 13, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03829527` - Evaluation of the Treatment Approach ROBIN	N/A
Recruiting	`NCT05827900` - Metacognitive Training in Ultra-high Risk	N/A
Recruiting	`NCT02951208` - tDCS Coupled With Virtual Rehabilitation for Negative Symptoms in At-Risk Youth	N/A
Completed	`NCT03983421` - Feasibility of an Early Detection Program for Early Psychosis on a College Campus
Recruiting	`NCT06037993` - Endocannabinoid Activity Remodulation for Psychosis Liability in Youth	N/A
Completed	`NCT02404194` - Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis	N/A
Completed	`NCT04444180` - The Predictive Role of Self-representation in Transition of Individuals at Clinical High Risk for Psychosis
Terminated	`NCT02047539` - Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis	Early Phase 1
Recruiting	`NCT05114733` - Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)	N/A
Completed	`NCT03303456` - Using Mobile Technology to Enhance Early Psychosis Treatment Delivery	N/A
Completed	`NCT03286595` - Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings	N/A
Terminated	`NCT02557945` - Gabapentin in Patients at Clinical Risk for Psychosis	Phase 1/Phase 2